From Palo Alto, California, USA:
My 63 year old mother, who lives in India and has had typeá2 diabetes for about 12 years, developed a foot ulcer, and doctors are recommending amputation of foot since there is risk of gangrene. She used medicines in capsule form for a long time, but, since her sugar levels was high, last year she started taking insulin. Despite this, her sugar levels remain high and she is not responding to increased doses of insulin. Is there any new type of insulin that would help? I am hoping that if her sugar levels are reduced, her injury will heal, and I want her to retain her foot.
I am sorry to hear about your mother. At the point where the foot ulcer is getting worse, it requires the combination of good blood sugar control, antibiotics, and wound debridement. This is a very labor intensive form of therapy. The healing is slow because of high sugars and also because blood flow is often compromised in the area of the ulcer (which does not allow the antibiotic to gain access to the wound).
There is no "best" insulin in this case. Usually, patients require multiple injections of long and short acting insulin with frequent blood sugar monitoring to document treatment success.
If the risk of leaving the foot on becomes so serious as to compromise your mother's life, the decision to amputate has to be addressed. I hope her doctors do not have to do this.
Original posting 26 Apr 2001
Posted to Complications
|Return to the Top of This Page|
Last Updated: Tuesday April 06, 2010 15:09:22
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
© Children with Diabetes, Inc. 1995-2018. Comments and Feedback.